AI Doctor's $40M Boost Fuels Prescription Revolution Amid Safety Fears

NEW YORK, NY – March 24, 2026 – Doctronic, the company behind the first artificial intelligence system legally authorized to practice medicine in the United States, has secured a $40 million Series B funding round, signaling intense investor confidence in a future where algorithms handle clinical tasks. The financing, co-led by Abstract and Lightspeed Venture Partners, brings the company's total funding to over $65 million in less than a year and follows a period of explosive growth.

The investment frenzy is directly tied to a landmark achievement in December 2025: Doctronic became the first AI to autonomously renew prescriptions for patients in Utah, operating within the state's pioneering regulatory sandbox. This move from providing information to taking direct clinical responsibility has positioned the company at the vanguard of a radical shift in healthcare delivery, but it has also ignited a fierce debate among medical professionals about safety, efficacy, and the future of patient care.

"Doctronic proved what we believed from the start: AI can deliver better healthcare outcomes at scale," said Ramtin Naimi, Partner at Abstract, in a statement. Lightspeed's Faraz Fatemi added, "They’ve built autonomous AI that integrates safely into real clinical workflows... uniquely delivering on the treatment through triage vision at an unmatched scale."

Utah's Sandbox: A New Frontier for AI in Medicine

Doctronic's ability to operate without direct, real-time physician oversight for every transaction is enabled by Utah's Artificial Intelligence Policy Act. Passed in 2024, the act created the AI Learning Lab, a regulatory sandbox allowing companies to test innovative systems under government supervision by temporarily waiving certain state rules.

Under a formal "Regulatory Mitigation Agreement," Doctronic's AI is permitted to make prescription renewal decisions for a predefined list of approximately 190 low-risk medications for patients with chronic conditions. The system is explicitly barred from handling higher-risk drugs like pain medications or ADHD treatments and cannot alter dosages.

This regulatory framework is built on a foundation of strict guardrails. The company must submit monthly reports to Utah's Office of Artificial Intelligence Policy (OAIP) and benchmark its performance against physician reviews. For each medication category, the first 250 prescriptions issued by the AI must be reviewed and validated by a human physician before the system can proceed autonomously. Furthermore, a built-in escalation protocol automatically flags complex cases or potential red flags, routing them to a 24/7 team of licensed physicians.

Crucially, Utah is regulating Doctronic as a limited-scope medical practitioner, not a medical device. This means that if an error occurs, the company is subject to the state's medical malpractice system, similar to a human doctor. This novel approach to liability is reinforced by what Doctronic calls a "first-of-its-kind AI medical malpractice insurance" policy, designed to establish clear lines of accountability and protect both patients and participating clinicians.

The Promise and Peril of Autonomous Care

Doctronic's market traction appears undeniable. The company reports its revenue has grown 15x to an eight-figure annualized run rate in the six months since its Series A, with its weekly user base swelling to over 300,000. Co-founder Dr. Adam Oskowitz attributes this to a superior clinical model. "Our AI performs dozens of safety checks per prescription renewal that would take a human physician an hour," he stated, citing a 99.2% treatment alignment rate.

However, this central claim has become a major point of contention. The 99.2% figure originates from a 500-patient study published as a non-peer-reviewed preprint. Researchers from a prominent U.S. medical university published a letter expressing "serious concern," noting that all the study's authors hold equity in Doctronic and that the study itself focused on diagnosing new issues in urgent care settings, a clinically distinct task from renewing chronic medications. They argue that even a small 0.8% error rate, when applied to hundreds of thousands of patients, could result in thousands of harmful events.

A leading national physician's association has also voiced skepticism, questioning the safety of removing a human clinician from the loop. The group highlighted that an AI lacks the human intuition to spot subtle signs that a routine renewal might be inappropriate or dangerous, a sentiment echoed by the Utah Academy of Family Physicians, which warned of risks like missed drug interactions and the masking of underlying health issues.

These concerns were amplified in March 2026 when a cybersecurity firm reported it had been able to "jailbreak" a Doctronic chatbot, causing it to produce unsafe medical advice. Doctronic and Utah's OAIP countered that the tested chatbot was a general-purpose tool, not the specialized and constrained AI deployed in the prescription pilot, which operates under multiple safeguards, including a secondary "guardian" AI that monitors for risky outputs.

Reshaping the Healthcare Marketplace

Despite the controversy, Doctronic is aggressively expanding. The new funding will fuel deeper partnerships with hospital systems, payers, and academic medical centers, as well as an expansion into pediatrics, a field where the company says consumer demand far outpaces access. The business model is multi-pronged: Doctronic serves as a "digital front door" for health systems to efficiently route their patients, offers payers a form of "unlimited primary care at predictable cost," and maintains a direct-to-consumer platform where AI consultations are free and prescription renewals cost just $4.

This strategy positions the company to disrupt multiple facets of the healthcare industry, from primary care clinics to traditional pharmacies. By automating routine tasks, the platform promises to lower costs, improve medication adherence—a major driver of poor health outcomes—and free up overworked clinicians to focus on more complex patient needs.

For investors, the combination of regulatory approval, rapid revenue growth, and a scalable platform represents a powerful formula. The company's success in Utah provides a potential roadmap for expansion into other states, with Doctronic confirming it is in active discussions with other regulators to expand its services.

The platform's architecture, which uses multiple specialized AI agents and enriches a proprietary dataset with each interaction, is designed to create a compounding data advantage that continuously improves its clinical accuracy. This model, which stands in stark contrast to AI-assisted tools where a human makes the final call, represents a high-stakes bet on the power of fully autonomous systems to redefine care delivery.

While the company touts a nearly tripled repeat patient rate as evidence of user trust and satisfaction, the broader medical community remains watchful. The convenience and affordability are clear draws for consumers, but the ultimate success of platforms like Doctronic will depend on their ability to consistently prove they are not just faster and cheaper, but fundamentally safe. The Utah experiment is not just a test for one company, but a real-world referendum on how far society is willing to trust an algorithm with its health.